Anti-inflammatory treatment in AD mice protects against neuronal pathology.
Prior studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may lower the incidence of Alzheimer's disease (AD) and delay onset or slow progression of symptoms in mouse models of AD. We examined the effects of chronic NSAID treatment in order to determine which elements of the pathological features might be ameliorated. We compared the effects of the NSAIDs ibuprofen and celecoxib on immunohistological and neurochemical markers at two different ages in APPxPS1 mice using measurements of amyloid plaque deposition, Abeta peptide levels, and neurochemical profiles using magnetic resonance spectroscopy (MRS). At 6 months of age, few neurochemical changes were observed between PSAPP mice and WT mice using MRS. Ibuprofen, but not celecoxib, treatment significantly decreased the Abeta(42/40) ratio in frontal cortex at 6 months, but overall amyloid plaque burden was unchanged. Consistent with prior findings in mouse models, at 17 months of age, there was a decrease in the neuronal markers NAA and glutamate and an increase in the astrocytic markers glutamine and myo-inositol in AD mice compared to WT. Ibuprofen provided significant protection against NAA and glutamate loss. Neither of the drugs significantly affected myo-inositol or glutamine levels. Both ibuprofen and celecoxib lowered plaque burden without a significant effect on Abeta(1-42) levels. NAA levels significantly correlated with plaque burden. These results suggest that selective NSAIDs (ibuprofen and possibly celecoxib) treatment can protect against the neuronal pathology.
Choi
Ji-Kyung
JK
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Jenkins
Bruce G
BG
Carreras
Isabel
I
Kaymakcalan
Sukru
S
Cormier
Kerry
K
Kowall
Neil W
NW
Dedeoglu
Alpaslan
A
D000367:Age Factors; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D005625:Frontal Lobe / Q000378:metabolism / Q000473:pathology; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D053763:Presenilins / Q000235:genetics / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*
D016229:Amyloid beta-Peptides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D053763:Presenilins; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D007052:Ibuprofen
Radiology. 1995 Apr;195(1):65-72
7892497
Nature. 2001 Nov 8;414(6860):212-6
11700559
Dev Neurosci. 1993;15(3-5):289-98
7805581
J Neurochem. 2000 May;74(5):2108-19
10800956
J Neurosci Res. 2001 Dec 1;66(5):891-8
11746416
N Engl J Med. 2001 Nov 22;345(21):1515-21
11794217
J Neurosci. 2002 Mar 15;22(6):2246-54
11896164
Science. 1996 Oct 4;274(5284):99-102
8810256
Neurobiol Aging. 2007 May;28(5):639-47
16697488
Magn Reson Med. 1995 Jun;33(6):858-61
7651126
Neurobiol Dis. 2005 Feb;18(1):32-9
15649694
Neuroreport. 2000 Jan 17;11(1):211-3
10683860
Brain Res. 2008 May 1;1207:225-36
18374906
J Neurochem. 1992 Jul;59(1):55-61
1613513
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11906-10
16091461
Trends Cell Biol. 2000 Dec;10(12):524-30
11121744
Brain Res. 2004 Jun 25;1012(1-2):60-5
15158161
Neurology. 2000 Jul 25;55(2):210-7
10908893
NMR Biomed. 2007 May;20(3):216-37
17451183
Glia. 2000 Dec;32(3):286-303
11102969
Trends Genet. 2006 May;22(5):281-9
16567017
Neurology. 2001 Mar 13;56(5):592-8
11261442